BTAI
BioXcel Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.07
−37.11%Margins
Gross margin
45.3%
EBITDA margin
-7198.2%
EBIT margin
-6014.4%
Net margin
-9549.9%
FCF margin
-6860.4%
61.4%
Return on equity
-246.1%
Return on assets
405.4%
Return on invested capital
0.02x
Asset turnover
-$50.9M
Cash from operations
$0.41
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026